NDAINHALATION, INJECTIONSOLUTION
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
XENEISOL (xenon xe-133) by Lantheus Medical Imaging is radiopharmaceutical activity [moa].
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XENEISOL (Xenon Xe-133) is a radiopharmaceutical inhalation and injection solution developed by Lantheus Medical Imaging for diagnostic imaging applications. It functions as a radioactive tracer that localizes to specific tissues, enabling visualization and assessment via nuclear medicine imaging techniques.
Pre-Launch
Early-stage radiopharmaceutical with limited current commercial visibility; team building and market development roles are likely priorities.
Mechanism of Action
Radiopharmaceutical Activity
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
XENEISOL represents an early-stage opportunity in diagnostic radiopharmaceuticals at Lantheus, a specialized medical imaging company. Joining this product now offers roles in pre-launch strategy, regulatory navigation, and building the commercial foundation for a niche diagnostic asset.
Brand ManagerProduct Manager
Worked on XENEISOL at Lantheus Medical Imaging? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.